Adaptive Biotechnologies Corp (ADPT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Adaptive Biotechnologies Corporation on December 30, 2025. The report details a financing event involving Digital Biotechnologies, Inc., a 70% owned subsidiary of the Company.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for Adaptive Biotechnologies Corporation. The only financial figure disclosed relates to the subsidiary's financing:
- Series A Financing Proceeds: Up to $15 million (total anticipated).
- Subsidiary Ownership: Digital Biotechnologies is currently 70% owned by Adaptive Biotechnologies.
Material Changes
On December 30, 2025, Digital Biotechnologies held the initial closing of its Series A Preferred Stock financing. Upon completion of this round, Adaptive Biotechnologies expects its ownership interest in Digital Biotechnologies to decrease to nearly 50%. Despite this dilution, the Company expects to continue consolidating Digital Biotechnologies' results in its financial statements.
Outlook, Risks, and Management Commentary
Management notes that Digital Biotechnologies is an early-stage company with no revenues and limited activities to date. The filing contains forward-looking statements regarding the completion of the financing, total proceeds, and future ownership percentages. These statements are subject to risks and uncertainties that may cause actual results to differ materially. The Company explicitly states it undertakes no obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Confirm the final total proceeds from the Digital Biotechnologies Series A round versus the anticipated $15 million.
- Verify the exact post-financing ownership percentage of Adaptive Biotechnologies in Digital Biotechnologies.
- Review the specific terms of the Series A Preferred Stock to understand potential dilution or liquidation preferences.
- Monitor future filings to confirm if the consolidation of Digital Biotechnologies continues as expected post-closing.